Research Report
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 21, 2014; 20(15): 4362-4369
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4362
Table 3 Univariate analysis of predictors for successful H.pylori eradication in per-protocol analysis
OR95%CIP value
Sex
Male1
Female0.9630.507-1.880.909
Age (yr)
< 601
≥ 601.10.594-2.090.754
Smoking
No1
Yes1.140.578-2.380.708
Drinking
No1
Yes0.6440.347-1.180.157
BMI
< 25
≥ 250.730.361-1.520.387
Clarithromycin
400 mg/d1
800 mg/d1.960.752-4.750.162
Diabetes Mellitus
No1
Yes0.6650.295-1.610.352
Hypertension
No1
Yes0.640.336-1.280.209
Lipid disorder
No1
Yes1.750.638-6.160.295
Chronic lung disease
No1
Yes1.680.278-32.00.616

  • Citation: Nishida T, Tsujii M, Tanimura H, Tsutsui S, Tsuji S, Takeda A, Inoue A, Fukui H, Yoshio T, Kishida O, Ogawa H, Oshita M, Kobayashi I, Zushi S, Ichiba M, Uenoyama N, Yasunaga Y, Ishihara R, Yura M, Komori M, Egawa S, Iijima H, Takehara T. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. World J Gastroenterol 2014; 20(15): 4362-4369
  • URL: https://www.wjgnet.com/1007-9327/full/v20/i15/4362.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v20.i15.4362